Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Receivables (2023 - 2025)

Profound Medical (PROF) has 3 years of Receivables data on record, last reported at $7.3 million in Q4 2025.

  • For Q4 2025, Receivables fell 1.02% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $7.3 million, down 1.02%, while the annual FY2025 figure was $7.3 million, 1.02% down from the prior year.
  • Receivables reached $7.3 million in Q4 2025 per PROF's latest filing, down from $7.7 million in the prior quarter.
  • Across five years, Receivables topped out at $7.7 million in Q3 2025 and bottomed at $5.0 million in Q1 2025.
  • Average Receivables over 3 years is $6.6 million, with a median of $7.3 million recorded in 2024.
  • Peak YoY movement for Receivables: decreased 0.72% in 2024, then dropped 1.02% in 2025.
  • A 3-year view of Receivables shows it stood at $7.4 million in 2023, then decreased by 0.72% to $7.4 million in 2024, then decreased by 1.02% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $7.3 million in Q4 2025, $7.7 million in Q3 2025, and $5.1 million in Q2 2025.